Save time and money with
Med Tech Market Research


MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Top 10 Biotech Companies
Market Outlook, 2008-2023

Publication Date: Dec 2008
Publisher: Visiongain
Pages: 157

 Price: £1,499.00
approximately: $2,171 | €1,597

Buy now >>
(managed by Piribo)

The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics — amongst others — the biotechnology market has experienced great expansion since its emergence during the 1970's.

The leading healthcare biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other healthcare biotech companies catching up.

The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market.

This report will help you to understand those developments and their significance. That report provides valuable commercial information on this exciting industry that no healthcare company should ignore.

Over the period 2008 to 2023, Visiongain foresees the healthcare biotechnological market continuing its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth.

However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development. There remain significant unmet needs in this market, with great opportunities for companies that can develop safer and better-targeted treatments.

Top-10 Biotech Companies — Market Outlook, 2008-2023 examines the product portfolios of the leading companies critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:

In particular, Top-10 Biotech Companies - Market Outlook, 2008-2023 concentrates on the following essential aspects of the healthcare biotech market:

  • Achievements and aspirations of global healthcare biotechnology
  • Detailed sales forecasts from 2008-2023 for the sector, leading biotech companies and their main products
  • Issues affecting the sector
  • Discussion of drivers and opportunities
  • Discussion of restraints and threats
  • Detailed analyses of the top-10 healthcare biotech companies from 2008 onwards
  • Salient pipeline developments in biotechnology and their implications for the future.

In 2007, the global revenues generated by the top-10 biotech companies exceeded $45bn. Amgen, Genentech and UCB are good examples of leading companies that have experienced strong sales growth in recent years. Principal drugs developed and marketed by the leading companies include Aranesp, Mabthera and Keppra, each with blockbuster sales. Moreover, pipelines of the leading biotech companies remain strong.

The leading healthcare biotechnology companies will continue to make strong inroads into the overall global pharma industry and market in the years ahead, with rising stars competing too.

Do you know how sales of leading biotech companies will develop over the coming years? Do you know the prospects for other biotech organisations? Visiongain concludes that there will be increasing reliance on biological drugs as time goes by, especially for recalcitrant diseases with significant unmet needs.

The commercial and technological opportunities for greater personalisation of medicine through biotechnology are very exciting. Certainly, the commercial opportunities for dynamic healthcare biotech companies are significant. The development of more-personalised medicine promising greater efficacy and safety — particularly in cancer treatment — is a major commercial hope. By purchasing this report, you will be better prepared to appreciate those major developments in the global pharmaceutical market.

Buy now >>

Contents

  • 1. Executive Summary
  • 2. Introduction to Biotechnology
    • 2.1 Background to Biotech Drugs
      • 2.1.1 Commonly-Used Terminology
      • 2.1.2 Summary of Recombinant DNA Technology
      • 2.1.3 Classes of Biotech Drugs
    • 2.2 Biotech Drugs are Gaining Increasing Importance
      • 2.2.1 Biopharmaceuticals are Versatile Agents
  • 3. The World Biotech Market Analysis & Forecast 2008 & 2023
    • 3.1 World Biotech Market Expanding Rapidly
    • 3.2 Biotech Market Revenues Grew Significantly in 2007
    • 3.3 Biotech Market Revenues Forecast 2008-2023
    • 3.4 The World Biotech Market is Dominated by North America
    • 3.5 Big Pharma Generates Strong Biotech Drug Revenues in 2007
    • 3.6 Amgen Records Largest Sales in the Global Biotech Industry in 2007
  • 4. Market Drivers and Restraints in the Global Biotech Market
    • 4.1 SWOT Analysis for the Biotech Market
    • 4.2 The Principal Drivers in the Biotech Market
    • 4.3 The Principal Restraints in the Biotech Market
    • 4.4 The Benefits of Biotechnology-Based Products
    • 4.5 Biotech Industry Market Capitalisation Gains Momentum
    • 4.6 Landmark Biotech Financing in 2007
    • 4.7 Healthcare Biotech Venture Capitalist Deals in 2007
    • 4.8 Healthcare Biotech VC Fund Investments
    • 4.9 Healthcare Biotech IPOs Funds in 2007
    • 4.10 New Technology Platforms in Biotech R&D
      • 4.10.1 The Application of Genomic Technology in R&D
      • 4.10.2 Leading Genomics Companies Benefit Through Lucrative Deals with Biotech and Big Pharma
      • 4.10.3 The Application of Proteomics in Drug Discovery Widens
    • 4.11 Pharmacogenomics is Crucial to Biotech Revenue Prospects
      • 4.11.1 Pharmacogenomics Holds Potential Benefits
      • 4.11.2 Biomarkers Add to Biotech Technology
    • 4.12 US-Style Advance Technology Platform (ATP)
    • 4.13 Collaborative Deals That Foster Genomic Applications
    • 4.14 Rapidly Expanding Biotech Market Has Marked Challenges Ahead
    • 4.15 Increasing Use of Pharmacoeconomic Evaluations is Having an Impact on Revenues of Biotech Medicines
    • 4.16 Biotech Companies Must Improve Safety Profile of Drugs
    • 4.17 Lack of Adequate Reimbursement Will Impede Potential Growth of the Biotech Market
    • 4.18 Potential Growth in Biogenerics (Biosimilars) Market Will Hamper Revenues of Branded Biotech Drugs
    • 4.19 EU Leads the Way in Biogenerics Market
    • 4.20 The US Awaits New Biogenerics Regulatory Framework
    • 4.21 US Congressional Budget Office (CBO) Estimates Biogenerics Will Help Reduce Drug Bills in the Long-Term
    • 4.22 Biogenerics Manufacturers Will Face Several Hurdles Despite Lucrative Prospects
    • 4.23 European Drug Regulation Framework Promises Increasing Entry of Biogenerics
    • 4.24 European Medicines Agency (EMEA) Amends its Biogeneric Regulation
    • 4.25 The Future of Healthcare Biotech looks Promising
  • 5. Top-10 Biotech Companies Forecast & Analyses 2008-2023
    • 5.1 Top-10 Biotech Companies Revenue Trends Looking Forward
  • 6. Amgen
    • 6.1 Key Therapeutic Areas
      • 6.1.1 Cancer
      • 6.1.2 Inflammation
      • 6.1.3 Neurology
  • 6 1.4 Metabolic Disorders
    • 6.1.5 Haematology
  • 6.2 Amgen Key Financials
  • 6.3 Amgen Revenue Forecast 2008-2023
  • 6.4 Amgen's Leading Drugs
    • 6.4.1 Amgen's Leading Drug Sales, 2007
  • 6.5 Amgen's Geographical Sales
  • 6.6 Amgen's Top-Three Drugs - Sales Forecasts 2008-2013
  • 6.7 Amgen's Phase III Pipeline
  • 7. Genentech
  • 7.1 Key Therapeutic Areas
  • 7.2 Genentech Key Financials
  • 7.3 Genentech Revenue Forecast 2008-2023
  • 7.4 Genentech's Leading Drugs
  • 7.5 Genentech's Geographical Sales
  • 7.6 Genentech's Top-Three Drugs - Sales Forecasts 2008-2013
  • 7.7 Genentech's Phase III Pipeline
  • 8. UCB
  • 8.1 Key Therapeutic Areas
  • 8.2 UCB Key Financials
  • 8.3 UCB Revenue Forecast 2008-2023
  • 8.4 UCB's Leading Drugs
    • 8.4.1 UCB's Leading Drugs Sales, 2007
  • 8.5 UCB's Geographical Sales
  • 8.6 UCB's Top-Three Drugs - Sales Forecasts 2008-2013
  • 8.7 UCB's Phase III Pipeline
  • 9. Gilead Sciences
  • 9.1 Key Therapeutic Areas
  • 9.2 Gilead Sciences Key Financials
  • 9.3 Gilead Sciences Revenue Forecast 2008-2023
  • 9.4 Gilead Sciences' Leading Drugs
  • 9.5 Gilead Sciences Geographic Sales
  • 9.6 Gilead Sciences' Top-Three Drugs - Sales Forecasts 2008-2013
  • 9.7 Gilead Sciences' Phase III Pipeline
  • 10. Genzyme
  • 10.1 Key Therapeutic Areas
  • 10.2 Genzyme Key Financials
  • 10.3 Genzyme Revenue Forecast 2008-2023
  • 10.4 Genzyme's Leading Drugs
  • 10.5 Genzyme's Geographical Sales
  • 10.6 Genzyme's Top-Three Drugs - Total Sales Forecasts 2008-2013
  • 10.7 Genzyme's Phase III Pipeline
  • 11. Biogen Idec
  • 11.1 Key Therapeutic Areas
  • 11.2 Biogen Idec Key Financials
  • 11.3 Biogen Idec Revenue Forecast 2008-2023
  • 11.4 Biogen Idec's Leading Drugs
  • 11.5 Biogen Idec's Geographical Sales
  • 11.6 Biogen Idec's Top-Two Drugs - Sales Forecasts 2008-2013
  • 11.7 Biogen Idec's Phase III Pipeline
  • 12. CSL
  • 12.1 Key Therapeutic Areas
  • 12.2 CSL Key Financials
  • 12.3 CSL Revenue Forecast 2008-2023
  • 12.4 CSL's Leading Drugs
  • 12.5 CSL's Geographical Sales
  • 12.6 CSL's Top-Three Drugs - Sales Forecasts 2008-2013
  • 12.7 CSL's Phase III Pipeline
  • 13. Cephalon
  • 13.1 Key Therapeutic Areas
  • 13.2 Cephalon Key Financials
  • 13.3 Cephalon's Revenue Forecast 2008-2023
  • 13.4 Cephalon's Leading Drugs
  • 13.5 Cephalon's Geographical Sales
  • 13.6 Cephalon's Top -Three Drugs - Sales Forecasts 2008-2013
  • 13.7 Cephalon's Phase III Pipeline
  • 14. Celgene
  • 14.1 Key Therapeutic Areas
  • 14.2 Celgene Key Financials
  • 14.3 Celgene Revenue Forecast 2008-2023
  • 14.4 Celgene's Leading Drugs
  • 14.5 Celgene's Geographical Sales
  • 14.6 Celgene's Top-Three Drugs - Sales Forecasts 2008-2013
  • 14.7 Celgene's Phase III Pipeline
  • 15. Actelion
  • 15.1 Key Therapeutic Areas
  • 15.2 Actelion Key Financials
  • 15.3 Actelion Revenue Forecast 2008-2023
  • 15.4 Actelion's Leading Drugs
  • 15.5 Actelion's Geographical Sales
  • 15.6 Actelion's Top-Three Drugs - Sales Forecasts 2008-2013
  • 15.7 Actelion's Phase III Pipeline
  • 16. Conclusions
  • 16.1 Biopharmaceutical Treatment Options Expand Significantly over Past Two Decades
  • 16.2 Biotech Industry Market Capitalisation Increases
  • 16.3 Biotech Market Generated Significant Revenues in 2007
  • 16.4 Overall Global Biotech Sales Prospects During the Forecast Period
  • 16.5 Prospects for the Top-10 Biotech Companies
  • 16.6 Big Pharma's Presence in the Biotech Arena
  • 16.7 Potential Growth in the Biogenerics Market
  • 16.8 The US Awaits Consolidation of Biogenerics Regulatory Framework
  • 16.9 Prospects for the Healthcare Biotech Market Leaders
  • List of Tables
    • Table 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
    • Table 3.2 Global Market Share (%) and Revenue ($m) by Country/Region, 2007
    • Table 3.3 Big Pharma's Biotech Revenue ($m), 2007
    • Table 3.4 Top-10 Biotech Companies ($m), 2007
    • Table 4.1 Biotech Market SWOT Analysis
    • Table 4.2 Biotech Market Capitalisation ($bn) over 10-Year Period, 1997-2007
    • Table 4.3 Patent Expiration of Leading Biotech Drugs
    • Table 5.1 Top-10 Biotech Companies Revenues ($m) Forecast, 2008-2023
    • Table 6.1 Amgen Revenues and Net Income ($m), 2003-2007
    • Table 6.2 Amgen: Total Corporate Revenues ($m), 2008-2023
    • Table 6.3 Amgen Leading Drug Sales ($m), 2007
    • Table 6.4 Amgen's Geographical Sales ($m), 2007
    • Table 6.5 Amgen's Top-Three Drugs - Sales ($m) Forecast, 2008-2013
    • Table 6.6 Amgen's Phase III Pipeline, 2008
    • Table 7.1 Genentech Revenues and Net Income ($m), 2003-2007
    • Table 7.2 Genentech: Total Corporate Revenues ($m), 2008-2023
    • Table 7.3 Genentech's Leading Drugs ($m), 2007
    • Table 7.4 Genentech's Geographical Sales ($m), 2007
    • Table 7.5 Genentech's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 7.6 Genentech's Phase III Pipeline, 2008
    • Table 8.1 UCB Revenues and Net Profit ($m), 2003-2007
    • Table 8.2 UCB: Total Corporate Revenues ($m), 2008-2023
    • Table 8.3 UCB's Leading Drugs ($m), 2007
    • Table 8.4 UCB's Geographical Sales ($m), 2007
    • Table 8.5 UCB's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 8.6 UCB's Phase III Pipeline, 2008
    • Table 9.1 Gilead Sciences Revenues ($m), 2003-2007
    • Table 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
    • Table 9.3 Gilead Sciences' Leading Drugs Sales ($m), 2006-2007
    • Table 9.4 Gilead Sciences' Geographical Sales ($m), 2007
    • Table 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 9.6 Gilead Sciences' Phase III Pipeline, 2008
    • Table 10.1Genzyme Revenues ($m), 2003-2007
    • Table 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
    • Table 10.3 Genzyme's Leading Products ($m), 2006-2007
    • Table 10.4 Genzyme's Geographical Sales ($m), 2006
    • Table 10.5 Genzyme's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 10.6 Genzyme's Phase III Pipeline, 2008
    • Table 11.1 Biogen Idec Revenues ($m), 2003-2007
    • Table 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
    • Table 11.3 Biogen Idec's Leading Drugs ($m), 2006-2007
    • Table 11.4 Biogen Idec's Geographical Sales ($m), 2006-2007
    • Table 11.5 Biogen Idec's Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 11.6 Biogen Idec's Phase III Pipeline, 2008
    • Table 12.1 CSL Revenues and Net Profit ($m), 2003-2007
    • Table 12.2 CSL: Total Corporate Revenues ($m), 2008-2023
    • Table 12.3 CSL's Leading Drugs ($m), 2006-2007
    • Table 12.4 CSL's Geographical Sales ($m), 2007
    • Table 12.5 CSL's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 12.6 CSL's Phase III Pipeline, 2008
    • Table 13.1 Cephalon's Revenues ($m), 2003-2007
    • Table 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
    • Table 13.3 Cephalon's Leading Drugs ($m), 2006-2007
    • Table 13.4 Cephalon's Geographical Sales ($m), 2007
    • Table 13.5 Cephalon's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 13.6 Cephalon's Phase III Pipeline, 2008
    • Table 14.1 Celgene's Revenues ($m), 2003-2007
    • Table 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
    • Table 14.3 Celgene's Leading Drugs ($m), 2006-2007
    • Table 14.4 Celgene's Geographical Sales ($m), 2006-2007
    • Table 14.5 Celgene's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 14.6 Celgene's Phase III Pipeline, 2008
    • Table 15.1 Actelion Revenues and Net Profit ($m), 2003-2007
    • Table 15.2 Actelion: Total Corporate Revenues ($m), 2008-2023
    • Table 15.3 Actelion's Leading Drugs ($m), 2006-2007
    • Table 15.4 Actelion's Geographical Sales ($m), 2006-2007
    • Table 15.5 Actelion's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Table 15.6 Actelion's Phase III Pipeline, 2008
  • List of Figures
    • Figure 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
    • Figure 3.2 Global Biotech Market Share (%), 2007
    • Figure 3.3 Big Pharma Biotech Market Share (%), 2007
    • Figure 3.4 Top-10 Biotech Companies Market Share (%), 2007
    • Figure 4.1 Biotech Market Capitalisation ($bn) over 10-Year Period 1997-2007
    • Figure 5.1 Top-10 Biotech Market Revenues ($m) Forecast, 2008-2023
    • Figure 6.1 Amgen Revenues ($m), 2003-2007
    • Figure 6.2 Amgen Net Income ($m), 2003-2007
    • Figure 6.3 Amgen: Total Corporate Revenues ($m), 2008-2023
    • Figure 6.4 Amgen's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 6.5 Amgen's Geographical Sales (%), 2007
    • Figure 6.6 Amgen's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 7.1 Genentech Revenues ($m), 2003-2007
    • Figure 7.2 Genentech Net Income ($m), 2003-2007
    • Figure 7.3 Genentech: Total Corporate Revenues ($m), 2008-2023
    • Figure 7.4 Genentech's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 7.5 Genentech's Geographical Sales (%), 2007
    • Figure 7.6 Genentech's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 8.1 UCB Revenues ($m), 2003-2007
    • Figure 8.2 UCB Net Profit ($m), 2003-2007
    • Figure 8.3 UCB: Total Corporate Revenues ($m), 2008-2023
    • Figure 8.4 UCB's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 8.5 UCB's Geographical Sales (%), 2007
    • Figure 8.6 UCB's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 9.1 Gilead Sciences Revenues ($m), 2003-2007
    • Figure 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
    • Figure 9.3 Gilead Sciences' Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 9.4 Gilead Sciences' Geographical Sales (%), 2007
    • Figure 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 10.1 Genzyme Revenues ($m), 2003-2007
    • Figure 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
    • Figure 10.3 Genzyme's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 10.4 Genzyme Geographical Sales (%), 2006
    • Figure 10.5 Genzyme's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 11.1 Biogen Idec Revenues ($m), 2003-2007
    • Figure 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
    • Figure 11.3 Biogen Idec's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 11.4 Biogen Idec's Geographical Sales (%), 2007
    • Figure 11.5 Biogen Idec's Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 12.1 CSL Revenues ($m), 2003-2007
    • Figure 12.2 CSL Net Profit ($m), 2003-2007
    • Figure 12.3 CSL: Total Corporate Revenues ($m), 2008-2023
    • Figure 12.4 CSL's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 12.5 CSL's Geographical Sales (%), 2007
    • Figure 12.6 CSL's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 13.1 Cephalon's Revenues ($m), 2003-2007
    • Figure 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
    • Figure 13.3 Cephalon's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 13.4 Cephalon's Geographical Sales (%), 2007
    • Figure 13.5 Cephalon's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 14.1 Celgene's Revenues ($m), 2003-2007
    • Figure 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
    • Figure 14.3 Celgene's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 14.4 Celgene's Geographical Sales (%), 2007
    • Figure 14.5 Celgene's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
    • Figure 15.1 Actelion Revenues ($m), 2003-2007
    • Figure 15.2 Actelion Net Profit ($m), 2003-2007
    • Figure 15.3 Actelion: Total Corporate Revenues ($m), 2008-2023
    • Figure 15.4 Actelion's Leading Drugs: Contribution to Company Sales (%), 2007
    • Figure 15.5 Actelion's Geographical Sales (%), 2007
    • Figure 15.6 Actelion's Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
  • Companies mentioned in report:
    • Abbott
    • Abgenix
    • Actelion
    • Amgen
    • Anthrogenesis
    • AstraZeneca
    • Biogen Idec
    • Bristol-Myers Squibb
    • Cardiokine Biopharm
    • Celera Genomics
    • Celgene
    • Cephalon
    • Chugai
    • CoTherix
    • CSL Ltd
    • CuraGen
    • Eisai
    • Eli Lilly
    • EMEA
    • FDA
    • Genentech
    • Genzyme
    • Gilead Sciences
    • GlaxoSmithKline (GSK)
    • Human Genome Sciences
    • Immunex-
    • Incyte Genomics
    • Iomai Corporation
    • Johnson & Johnson (J&J)
    • MedImmune
    • Merck KGaA
    • MGI
    • Millennium Pharmaceuticals
    • Mundipharma
    • Myriad Genetics
    • Novartis
    • Novo Nordisk
    • Pfizer
    • Pharmion
    • Roche
    • Roche Centre for Medical Genomics (RCMG)
    • Sanofi-Aventis
    • Schering-Plough
    • Schwarz Pharma
    • Serono (now Merck Serono)
    • Signal Pharmaceuticals
    • Teva
    • UCB
    • US Congressional Budget Office (CBO)
    • Ventana Medical Systems
    • World Health Organisation (WHO)
    • Wyeth
    • Zenyaku

Buy now >>

To top